PharmTech AI Pulse Check episode 2 covers AI data governance, API-gated journals, watermarking limits, and why attribution beats detection in GxP.
|Articles|March 19, 2020
Thermo Fisher Scientific
Author(s)Thermo Fisher Scientific
Thermo Fisher Scientific provides end- to-end development and manufacturing solutions to customers through Patheon and Fisher Clinical Services.
Thermo Fisher Scientific provides end- to-end development and manufacturing solutions to customers through Patheon and Fisher Clinical Services. With more than 40 locations around the world, the company has extensive capabilities including drug substance, and product development, viral vector services, clinical trials, and commercial- scale manufacturing.
Thermo Fisher Scientific
4815 Emperor Blvd. Suite 110, Durham, NC 27703
tel. 919.226.3200
pharmaservices@thermofisher.com
Related to this article
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.
Ron Scarboro, Azurity Pharmaceuticals, explains why real-world usability belongs at product definition and how post-launch feedback should guide drug formulation.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Gene manufacturing platforms, patient-centric formulations, contract services, packaging innovations, and sterile filling lines are in the spotlight at CPHI Milan 2026.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.